General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Stocks Churn as Traders Waver on US Rates Outlook: Markets Wrap | news.google.com • |
Microsoft Stock Outlook: Is MSFT a Millionaire-Maker AI Play to Make? | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | -0.88 | -1.55 | -0.67 | -76.14% |
2024-02-14 | 2023-12 | -1 | -0.8 | 0.2 | 20.00% |
2023-12-22 | 2023-09 | -1 | -1 | N/A | N/A |
2023-08-14 | 2023-06 | -0.8 | -1.6 | -0.8 | -100.00% |
2023-05-15 | 2023-03 | -1.2 | -0.6 | 0.6 | 50.00% |
2023-02-14 | 2022-12 | -0.8 | -1.6 | -0.8 | -100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Chardan Capital | Downgrade | Buy | Neutral |
2023-08-30 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-08-29 | Brookline Capital | Downgrade | Buy | Hold |
2023-08-29 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
2023-08-29 | BTIG | Downgrade | Buy | Neutral |
2023-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-04-19 | DAGNON TERRY | Chief Operating Officer | 653.06K | Sale |
2024-03-06 | EVANSON JEFF | Officer | 808.46K | Purchase |
2024-03-27 | HADDADIN YEZAN MUNTHER | Director | 5.05K | Purchase |
2022-10-04 | HILZINGER KURT J | Director | 473.12K | Purchase |
2021-04-19 | KENYON LAWRENCE A. | Chief Executive Officer | 18.93K | Purchase |
2022-10-06 | SUKHTIAN FAISAL GHIATH | Director | 68.00K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 9.22M | 16.04M | 3.54% |
2023-06-29 | Vanguard Group Inc | 6.15M | 10.70M | 2.36% |
2023-06-29 | State Street Corporation | 2.75M | 4.79M | 1.06% |
2023-06-29 | Geode Capital Management, LLC | 2.72M | 4.73M | 1.05% |
2023-06-29 | Northern Trust Corporation | 1.26M | 2.18M | 0.48% |
2023-06-29 | Nuveen Asset Management, LLC | 598.96K | 1.04M | 0.23% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.61M | 6.28M | 1.39% |
2023-08-30 | iShares Russell 2000 ETF | 3.58M | 815.24K | 1.37% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.45M | 2.52M | 0.56% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.38M | 2.38M | 0.53% |
2023-08-30 | iShares Russell 2000 Growth ETF | 1.27M | 289.29K | 0.49% |
2023-05-30 | Fidelity Extended Market Index Fund | 519.75K | 779.62K | 0.20% |
Split | Date |
---|---|
1 : 20 | 2024-03-14 |
1 : 8 | 2019-03-18 |
Mbappe, the only problem with 10% market capture is that it doesn't factor in market exclusivity. Upon approval all off label must stop due to patent exclusivity. Simply put patients can convert or go blind. I don't know pricing but believe the increase in price will still leave this the least approved therapy on market. I believe 100% of compounding business will be captured
Frank Chance, you are a long way from th$7.00 short sale. Get out before you lose your house. Pride is going to cost you dearly here. Just admit you got this one wrong.
Bernie Forrester, future revenue should cap out at about $200-300 a share with current market information. There is about another year and a half to wait. Patience is a virtue.
Where is the short sided “Wiz cheese” now or “not being Frank” and all the other alias he goes by. Did not fool anyone. Maybe when he predicted .10 cents he was confused and misplaced the decimal?? I am sure he meant $10 dollars. Time to change your name again continue your uniformed abrasive behavior elsewhere. Must be lonely not having any friends!
Brad, I like your thinking. I think you are conservatively low on sales for EU. The US will be a much larger market mid to late 2025. Price resistance will be all but nil. It will still be the least expensive and safest medicine on market with regulatory approval. Remember failure to treat will lead to blindness.
Angelo Dilanni I have been in Pharma for over 25 years and have never seen a cleaner application than Otlk for approval in Europe. superior safety, and efficacy study already done Norse 2 and the National Eye Institute CATT study done in 2005. The current FDA required study is a CATT repeat study so statistically the outcome is already known. Not to mention almost two decades of off-label use of this compound makes this a very established form of treatment(if the was a problem, we would already know).These approvals would finally give EMA and FDA regulatory control of this therapy. There is no company debt and way more money than needed to manufacture and market. The only question left is, did they resolve the CMC issues and this would only slow the process not stop it. It should be noted there has been plenty of time to resolve any FDA issues.
Tick, tock, tick, tock, the music is about to stop! He devil is about to collect his due. The day trading short are about to pay a fortune for the few actual stocks being traded. Recycled short sales are going to dry up. Who will get out and who will get stuck? I'm going to go start the popcorn.
Frank Chance is back. He is talking like he is worried…… he should be!
Derek Danial, you may want to get a broker to help you. Based on all your statements… I don't think you have a clue what's going on or how things are done. My advice is done go to deep on your first trades and maybe pick up some educational books on trading. Last tip: font listen to The Wiz, Waldo_III or Frank Chance. Clueless doesn't begin to describe their insight on stocks.
every short seller has a buyer, but every Buyer won’t have a seller
I am still buying and when you need me to cover your short gambling habit… I won't!!!! Call it tough love and a lesson about greed. The time of the short is quickly coming to an end.
Derick Danial, that is absolutely not how it work!
The more the shorts sell… the bigger the trap!
Why would anyone be selling???? Is there a reasonable explanation? Any ideas at all???
If you are hoingbto buy more.… now is the time!!!
You won't see OTLK this cheap ever again
Go shorts go!!! Im long and will not sell during the run away. The study is done approval is eminent approval. All debt is moved to stock…. So no loans to worry about and all the money secured for launch in $19billion market half already capture do to market patent exclusivity. If you have doubts on approval you didn't do your homework. FDA only asked for a reenactment of a National Eye Institute study done over a decade ago. The shorts are loading the market with a gluttony of shares they will never be able to cover. Yes they are driving price done for the moment but when the music stops the mad scramble will begin. Go shorts go! There are not enough shares to cover.
Randomized Controlled Trial
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
CATT Research Group et al. N Engl J Med. 2011.
Show details
Full text links
Cite
Abstract
Background: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data.
Methods: In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart.
Results: Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, P=0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern.
Conclusions: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.).
PubMed Disclaimer
Woody Walls you lost your money because you don't know what you are doing. Misery loves company quit trying to pull others down with your ignorance. The money is a the finish line of approval. You dropped out an sold to the Wiz, Frank Chance, Waldo_III and I ️animal
Studies. They took your money and are now laughing at you.
Frank Chance, you are a penny flipper with no understanding of how to make the big money. Based on your gambling disclosures, I believe you are still down money. The number of clown faces seem to mirror your loses.